Latest Mucopolysaccharidosis Stories
CALABASAS, Calif., April 8, 2015 /PRNewswire/ -- ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced
LEXINGTON, Mass., Jan.
SOUTH PLAINFIELD, N.J., Dec. 19, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S.
LEXINGTON, Mass., Dec.
CALABASAS, Calif., Dec.
ReportsnReports.com adds “Mucopolysaccharidosis I and II (MPS I & II) (Hurler Syndrome) - Pipeline Review, H2 2014” to its store.
Strengthens Leadership Position in Treatments for Hunter syndrome and Commitment to MPS II Patient Community LEXINGTON, Massachusetts, July 23, 2014 /PRNewswire/ --
ArmaGen to Receive up to Approximately $225 Million Including Initial Upfront Payment of $15 Million in Cash and Equity, an Additional Equity Investment, R&D Funding, Development and Sales Milestones,
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).